The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies
Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.
In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.